Trial reportBiological psychiatry2012
Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Trial report in Biological psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 61 citations in OpenAlex.
- Reward drinking and naltrexone treatment response among young adult heavy drinkers.Addiction (Abingdon, England) · 2021Trial
- Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking.Alcoholism, clinical and experimental research · 2019Trial
- Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.Alcoholism, clinical and experimental research · 2018Trial
- Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial.JAMA psychiatry · 2018Trial
- Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015Trial
- A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.Psychopharmacology · 2015Trial
- Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.Alcoholism, clinical and experimental research · 2015Trial
- Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.Alcoholism, clinical and experimental research · 2014Trial
- Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.Addiction (Abingdon, England) · 2013Trial
- Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.Biological psychiatry · 2013Trial
- Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis.Journal of addiction medicineTrial
- Evidence of subgroup differences in meta-analyses evaluating medications for alcohol use disorder: An umbrella review.Alcohol, clinical & experimental research · 2024Review
- Hazardous drinking and alcohol use disorders.Nature reviews. Disease primers · 2022Review
- Smoking As an Outcome Moderator In the Treatment of Alcohol Use Disorders.Alcohol and alcoholism (Oxford, Oxfordshire) · 2022Review
- The incentive amplifying effects of nicotine: Roles in alcohol seeking and consumption.Advances in pharmacology (San Diego, Calif.) · 2022Review
- The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials.Addictive behaviors · 2021Article
- Smoking reduction is associated with lower alcohol consumption and depressive symptoms among young adults over one year.Drug and alcohol dependence · 2021Article
- Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving.Molecular psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundIdentifying factors that modify responsiveness to pharmacotherapies for alcohol dependence is important for treatment planning. Cigarette smoking predicts more severe alcohol dependence and poorer treatment response in general. Nevertheless, there is limited research on cigarette smoking as a potential predictor of differential response to pharmacological treatment of alcoholism.
methodsWe examined the association between cigarette smoking and drinking outcomes in the COMBINE (Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence) study, a randomized, double-blind placebo-controlled 16-week trial comparing combinations of medications (i.e., acamprosate and naltrexone) and behavioral interventions (i.e., medical management, combined behavioral therapy) in 1383 alcohol-dependent individuals.
resultsSmokers (i.e., more than one half the sample) significantly differed from nonsmokers on several demographic and drinking-related variables at baseline and generally had poorer treatment outcomes than nonsmokers. However, smokers who received naltrexone had better drinking outcomes than smokers who received placebo, whereas alcohol use among nonsmokers did not vary by naltrexone assignment. This pattern of findings occurred independent of whether patients received combined behavioral intervention or medical management and remained after controlling for alcoholism typology and baseline demographic differences. Approximately 9% of smokers quit smoking, and an additional 10% reduced their cigarette intake during treatment. Reductions in smoking did not vary by treatment assignment.
conclusionsThese results suggest that naltrexone might be particularly beneficial for improving alcohol use outcomes in alcohol-dependent smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.